Principal Investigator/Program Director (Last, First, Middle):
Winter, Patrick Matthew
BIOGRAPHICAL SKETCH
Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. DO NOT EXCEED FOUR PAGES.
NAME
POSITION TITLE
Winter, Patrick Matthew
Research Assistant Professor of Medicine and
Biomedical Engineering
eRA COMMONS USER NAME
PWINTER
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)
INSTITUTION AND LOCATION
Washington University, St. Louis, MO
University of Texas, Southwestern, Dallas, TX
Washington University, St. Louis, MO
DEGREE
(if applicable)
YEAR(s)
BS
Ph.D.
Post-Doc
1994
2000
2000-2002
FIELD OF STUDY
Electrical Engineering
Biomedical Engineering
Biomedical Engineering
Please refer to the application instructions in order to complete sections A, B, and C of the Biographical
Sketch.
A. Positions and Honors.
Positions and Employment
1995-1998
Research Assistant, University of Texas, Southwestern, Dallas, TX
1998-2000
Research Assistant, University of Pennsylvania, Philadelphia, PA
2000-2002
Post-Doctoral Fellow, Washington University, St. Louis, MO
2002-2005
Instructor of Medicine, Washington University, St. Louis, MO
2005-Present Assistant Professor of Medicine, Washington University, St. Louis, MO
2006-Present Affiliate Assistant Professor of Biomedical Engineering, Washington University, St. Louis, MO
Other Experience and Professional Memberships
1995Member, Biomedical Engineering Society
1996Member, Tau Beta Pi Engineering Honor Society
1996
Treasurer, Local Biomedical Engineering Society Chapter
1998Member, International Society of Magnetic Resonance in Medicine
2001Member, Society for Cardiovascular Magnetic Resonance
2002Member, Society for Molecular Imaging
Honors
1990-1994
2000-2002
2000, 2001
2002
2003
2005
Academic Scholarship, Washington University School of Engineering
NIH Institutional Training Grant, Washington University
ISMRM Travel Award
Burroughs Wellcome Fund Career Award Nominee, Washington University
First Place, Best Abstract Competition, Society for Cardiovascular Magnetic Resonance
Second Place, Best Abstract Competition, Society for Cardiovascular Magnetic Resonance
B. Peer-Reviewed Publications (in chronological order).
1. Winter PM, Seshan V, Makos JD, Sherry AD, Malloy CR, Bansal N. Quantitation of intracellular [Na+] in vivo
using TmDOTP5- as an NMR shift reagent and extracellular volume marker. J Appl Physiol, 85:1806-1812, 1998.
2. Winter P, Bansal N, Magnetic Resonance, General Medical, In “Encyclopedia of Analytical Chemistry:
Applications, Theory, and Instrumentation” (RA Meyers Ed.), London: John Wiley & Sons, 2000, pp. 201-236.
3. Winter PM, Poptani H, Bansal N. Effects of chemotherapy by 1,3-Bis(2-chloroethyl)-1-nitrosourea on singlequantum and triple-quantum-filtered 23Na and 31P nuclear magnetic resonance of the subcutaneously implanted
9L glioma. Cancer Res, 61:2002-2007, 2001.
4. Winter PM, Bansal N. TmDOTP5- as a 23Na NMR shift reagent for the subcutaneously implanted 9L gliosarcoma
in rats. Mag Reson Med, 45:436-442, 2001.
5. Zhang S, Winter P, Wu K, Sherry AD. A novel europium(III)-based MRI contrast agent. J Am Chem Soc,
123:1517-1518, 2001.
PHS 398/2590 (Rev. 09/04, Reissued 4/2006)
Page
Biographical Sketch Format Page
Principal Investigator/Program Director (Last, First, Middle):
Winter, Patrick Matthew
6. Winter PM, Bansal N. Evaluation of triple-quantum-filtered 23Na MR spectroscopy of subcutaneously implanted
9L gliosarcoma in the presence of TmDOTP5-. J Magn Reson, 152:70-78, 2001.
7. Flacke S, Fischer S, Scott MJ, Fuhrhop RJ, Allen JS, McLean M, Winter P, Sicard GA, Gaffney PJ, Wickline SA,
Lanza GM. A novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable
plaques. Circulation, 104:1280-1285, 2001.
8. Lanza GM, Abendschein DA, Yu X, Winter PM, Karukstis KK, Scott MJ, Fuhrhop RW, Scherrer DE, Wickline SA.
Molecular imaging and targeted drug delivery with a novel, ligand-directed paramagnetic nanoparticle technology.
Acad Radiol, 9:S330-331, 2002.
9. Lanza GM, Yu X, Winter PM, Abendschein DA, Karukstis KK, Scott MJ, Chinen LK, Fuhrhop RW, Scherrer DE,
Wickline SA. Targeted antiproliferative drug delivery to vascular smooth muscle cells with an MRI nanoparticle
contrast agent: implications for rational therapy of restenosis. Circulation, 106:2842-2847, 2002.
10. Winter PM, Caruthers SD, Yu X, Song SK, Fuhrhop RW, Chen J, Miller B, Bulte JWM, Wickline SA, Lanza GM.
Improved molecular imaging contrast agent for detection of human thrombus. Mag Reson Med, 50:411-416,
2003.
11. Winter PM, Caruthers SD, Kassner A, Harris TD, Chinen LK, Allen JS, Zhang H, Robertson JD, Wickline SA,
Lanza GM. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel v3-targeted
nanoparticle and 1.5 Tesla MRI. Cancer Res, 63:5838-5843, 2003.
12. Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams T, Allen JS, Robertson JD, Lanza GM,
Wickline SA. Molecular imaging of angiogenesis in early-stage atherosclerosis with v 3-integrin-targeted
nanoparticles. Circulation, 108:2270-2274, 2003.
13. Morawski AM, Winter PM, Crowder KC, Caruthers SD, Fuhrhop RW, Scott MJ, Robertson JD, Abendschein DR,
Lanza GM, Wickline SA. Targeted Nanoparticles for Quantitative Imaging of Sparse Molecular Epitopes with MRI.
Mag Reson Med, 51:480-486, 2004.
14. Morawski AM, Winter PM, Yu X, Fuhrhop RW, Scott MJ, Hockett FD, Robertson JD, Gaffney PJ, Lanza GM,
Wickline SA. Quantitative "magnetic resonance immunohistochemistry" with ligand-targeted 19F nanoparticles.
Mag Reson Med, 52:1255-1262, 2004.
15. Lanza GM, Winter PM, Caruthers SD, Schmeider AH, Crowder KC, Morawski AM, Zhang H, Scott MJ, Wickline
SA, Novel Paramagnetic Contrast Agents for Molecular Imaging and Targeted Drug Delivery. Curr Pharm
Biotechnol, 5:495-507, 2004.
16. Lanza GM, Winter PM, Caruthers SD, Morawski AM, Schmieder AH, Crowder KC, Wickline SA. MR molecular
imaging with nanoparticles: from bench to bedside. J Nucl Cardiol, 11:733-743, 2004.
17. Winter PM, Caruthers SD, Wickline SA, Lanza GM, Nanotechnologies for Cellular and Molecular Imaging by MRI,
In “Nanofabrication Towards Biomedical Applications” (C Kumar, J Hormes, C Leuschner Eds.), Weinheim: WileyVCH, 2005, pp. 227-249.
18. Schmieder AH, Winter PM, Caruthers SD, Harris TD, Williams TA, Allen JS, Lacy EK, Zhang H, Scott MJ, Hu G,
Robertson JD, Wickline SA, Lanza GM. Molecular MR imaging of melanoma angiogenesis with v3-targeted
paramagnetic nanoparticles. Mag Reson Med, 53:621-627, 2005.
19. Winter P, Athey P, Kiefer G, Gulyas G, Fuhrhop R, Robertson D, Wickline S, Lanza G. Improved paramagnetic
chelate for molecular imaging with MRI. J Magn Magn Mater, 293:540-545, 2005.
20. Winter PM, Shukla HP, Caruthers SD, Scott MJ, Fuhrhop RW, Robertson JD, Gaffney PJ, Wickline SA, Lanza
GM Molecular imaging of human thrombus with computed tomography. Acad Radiol, 12:9-13, 2005.
21. Winter PM, Athey PS, Kiefer GE, Gulyas G, Fuhrhop RW, Robertson JD, Wickline SA, Lanza GM. Improved
paramagnetic chelate for molecular imaging with MRI. Acad Radiol, 12:40-41, 2005.
22. Winter PM, Caruthers SD, Harris TD, Schmieder AH, Abendschein D, Cyrus T, Fuhrhop RW, Dietz EK, Williams
TA, Allen JS, Zhang H, Wickline SA, Lanza GM. Molecular imaging of v3-integrin: an opportune biochemical
signature For oncologic and cardiovascular diseases. Acad Radiol, 12:43, 2005.
23. Cyrus T, Winter PM, Caruthers SD, Wickline SA, Lanza GM. Magnetic resonance nanoparticles for
cardiovascular molecular imaging and therapy. Expert Rev Cardiovasc Ther, 3:705-715, 2005.
24. Lanza GM, Winter PM, Neubauer AM, Caruthers SD, Hockett FD, Wickline SA. 1H/19F magnetic resonance
molecular imaging with perfluorocarbon nanoparticles. Curr Top Dev Biol, 70:57-76, 2005.
25. Caruthers SD, Winter PM, Wickline SA, Lanza GM, Targeted Magnetic Resonance Imaging Contrast Agents, In
“Magnetic Resonance Imaging: Methods and Biologic Applications” (PV Prasad, Ed.), Totowa, NJ: Humana Press
Inc., 2005, pp. 387-400.
26. Wickline SA, Neubauer AM, Winter PM, Caruthers SD, Lanza GM. Applications of Nanotechnology to
Atherosclerosis, Thrombosis, and Vascular Biology. Arterioscler Thromb Vasc Biol, 26:435-441, 2006.
27. Caruthers SD, Neubauer AM, Hockett FD, Lamerichs R, Winter PM, Scott MJ, Gaffney PJ, Wickline SA, Lanza
GM. 19F MR imaging and spectroscopy enhance molecular imaging with paramagnetic perfluorocarbon
nanoparticles on 1.5T clinical scanners. Invest Radiol, 41:305-312, 2006.
28. Winter PM, Caruthers SD, Wickline SA, Lanza GM. Molecular Imaging by MRI. Curr Cardiol Rep, 8:65-69, 2006.
PHS 398/2590 (Rev. 09/04, Reissued 4/2006)
Page
Continuation Format Page
Principal Investigator/Program Director (Last, First, Middle):
Winter, Patrick Matthew
29. Caruthers SD, Winter PM, Wickline SA, Lanza GM. Targeted magnetic resonance imaging contrast agents.
Methods Mol Med, 124:387-400, 2006.
30. Lanza GM, Hughes MS, Winter PM, Caruthers SD, Marsh JN, Morawski AM, Schmieder AH, Scott MJ, Fuhrhop
RW, Zhang H, Hu G, Lacy EK, Allen JS, Wickline SA, Molecular Imaging and Therapy: New Paradigms for 21st
Century Medicine, In “Polymeric Drug Delivery I: Particulate Drug Carriers” (S Svenson, Ed.), New York: Oxford
University Press, 2006, pp. 295-311.
31. Winter PM, Neubauer AM, Caruthers SD, Harris TD, Robertson JD, Williams TA, Schmieder AH, Hu G, Allen JS,
Lacy EK, Zhang H, Wickline SA, Lanza GM. Endothelial v3-integrin targeted Fumagillin nanoparticles inhibit
angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol, 26:2103-2109, 2006.
32. Winter PM, Cai K, Chen J, Adair CR, Kiefer GE, Athey PS, Gaffney PJ, Buff, CE, Robertson JD, Caruthers SD,
Wickline SA, Lanza GM. Molecular imaging of fibrin with a targeted PARACEST nanoparticle contrast agent. Mag
Reson Med, 56:1384-1388, 2006.
33. Lanza GM, Winter PM, Cyrus T, Caruthers SD, Marsh JN, Hughes MS, Wickline SA. Nanomedicine opportunities
in cardiology. Ann N Y Acad Sci, 1080:451-465, 2006.
34. Cyrus, T, Winter PM, Caruthers SD, Wickline SA, Lanza GM. Nanoparticles for Magnetic Resonance Imaging of Tumors. In
“Nanomaterials for Cancer Therapy and Diagnosis” (C Kumar, Ed.), Weinheim: Wiley-VCH, 2007, pp. 121-146.
35. Wickline SA, Neubauer AM, Winter P, Caruthers S, Lanza G. Targeted nanoparticle contrast agents for vascular molecular
imaging and therapy. In “The Vulnerable Plaque” (Waksman R, Serruys PW, Schaar J, Eds.), Abingdon, UK: Informa
Healthcare, 2007, pp. 289-302.
36. Adair C, Woods M, Zhao P, Pasha A, Winter PM, Lanza GM, Athey P, Sherry AD, Kiefer GE, Spectral properties of
37.
38.
39.
40.
a bifunctional PARACEST europium chelate: an intermediate for targeted imaging applications. Contrast Media
Mol Imaging, 2:55-58, 2007.
Winter PM, Cai K, Caruthers SD, Wickline SA, Lanza GM. Emerging nanomedicine opportunities with
perfluorocarbon nanoparticles. Expert Rev Med Devices. 4:137-145, 2007.
Wickline SA, Neubauer AM, Winter PM, Caruthers SD, Lanza GM. Molecular imaging and therapy of
atherosclerosis with targeted nanoparticles. J Magn Reson Imaging, 25:667-680, 2007.
Tran TD, Caruthers SD, Hughes M, Marsh JN, Cyrus T, Winter PM, Neubauer AM, Wickline SA, Lanza GM.
Clinical applications of perfluorocarbon nanoparticles for molecular imaging and targeted therapeutics.
International Journal of Nanomedicine, 2:515-526, 2007.
Winter PM, Caruthers SD, Schmieder AH, Neubauer AM, Lanza GM, Wickline SA. Molecular MR Imaging with
Paramagnetic Perfluorocarbon Nanoparticles. In: “Nanoparticles in Biomedical Imaging: Emerging Technologies
and Applications” (Bulte JW, Modo M, Eds.), New York: Springer, 2008, pp. 163-182.
C. Research Support.
Ongoing Research Support
RO1-EB-01704 (PI: Winter)
04/01/2004-01/31/2009
NIH, National Institute of Biomedical Imaging and Bioengineering
“Molecular Imaging of Angiogenesis by MRI”
The primary aims of this research are: 1) Developing animal models of peripheral vascular disease coupled with
atherosclerosis, 2) Optimize molecular imaging techniques in the rabbit, and 3) Utilizing alpha(v)beta(3)-targeted
nanoparticles to demonstrate molecular imaging of angiogenesis.
Role: Principal Investigator
U54-CA-119342 (PI: Wickline)
9/30/2005-8/31/2010
NIH, National Cancer Institute
“The Siteman Center of Cancer Nanotechnology Excellence”
This proposal applies a novel paramagnetic site-targeted contrast "platform technology" for the sensitive and specific
imaging of molecular epitopes expressed on tumor neovasculature alone and in combination with the local delivery of
chemotherapeutic agents.
Role: Co-Investigator
RO1-HL-078631 (PI: Lanza)
9/01/2004- 8/31/2008
NIH, National Heart, Lung and Blood Institute
“Combined Therapeutic-Imaging Agent for Atherosclerosis”
The ultimate aim of this proposal is to demonstrate magnetic resonance molecular imaging of plaque neovasculature in
conjunction with local anti-angiogenic therapy.
Role: Co-Investigator
PHS 398/2590 (Rev. 09/04, Reissued 4/2006)
Page
Continuation Format Page
Principal Investigator/Program Director (Last, First, Middle):
Winter, Patrick Matthew
R01-HL-073646 (PI: Wickline)
07/15/2004-06/30/2009
NIH, National Heart, Lung and Blood Institute
“Methods in Molecular Imaging and Targeted Therapeutics”
The long-range goal is to produce a targeted nanoparticle contrast agent characterized by: 1) flexible
targeting options depending on the binding ligand selected, 2) flexible imaging choices based on contrast mechanism best
suited to the pathology in question, and 3) flexible opportunities for local delivery of therapeutic agents coupled directly
with image-based quantification of local nanoparticle deposition.
Role: Co-Investigator
Completed Research Support
0235125N (PI: Winter)
07/01/2002-06/30/2007
American Heart Association
“Monitoring Angiogenic Therapy by Noninvasive MRI Using a Targeted Paramagnetic Nanoparticle Contrast Agent”
The major goals of this research are: 1) Optimize avb3-targeted nanoparticle emulsions for use as in vivo targeted
contrast agents; 2) Characterize angiogenesis in a rabbit hindlimb ischemia model; and 3) Demonstrate early detection of
response to angiogenic therapy with avb3-targeted nanoparticles.
Role: Principal Investigator
N01-CO-37007-16 (PI: Lanza)
09/30/2003-09/29/2006
NIH, National Cancer Institute
“Molecular Imaging and Therapy of Solid Tumors With a Novel avb3-Directed Nanoparticle Targeted to the
Neovasculature”
The ultimate aims of this contract are to demonstrate the feasibility of this unique, targeted diagnostic and therapeutic
technology to detect angiogenesis associated with solid tumors and to deliver local therapy.
Role: Co-Investigator
(PI: Winter)
01/01/2003-12/31/2003
Barnes-Jewish Hospital Foundation
Validation of Molecular Imaging by Noninvasive MRI Using a Targeted Paramagnetic Nanoparticle Contrast Agent.
The major goals of this research are 1) to validate animal models of hindlimb ischemia using x-ray angiography as the
gold standard; 2) correlate nanoparticle contrast enhancement with angiographic scoring; and 3) compare MRI and x-ray
angiography methods.
Role: Principal Investigator
PHS 398/2590 (Rev. 09/04, Reissued 4/2006)
Page
Continuation Format Page